Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
Key Highlights
- ➤Vivos acquired 11% of SOD Sciences and 50% of its pseudohypoxia test.
- ➤Vivos issued $12 million of Series C preferred stock; no cash changed hands.
- ➤Conversion price $0.15 could create up to 80 million common shares.
- ➤Expected transaction impact: more than $10 million added to stockholders’ equity.
- ➤AHA channel could reach more than 325,000 patients, pending agreements and bankruptcy approval.
Expert Statements
R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos Therapeutics
“Today Vivos became more than a healthcare company just treating sleep apnea”
R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos Therapeutics
“We expect this transaction to add more than $10 million to our stockholders’ equity, and we now own half of a test designed to identify patients whose sleep apnea may be contributing to chronic disease.”
R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos Therapeutics
“With more than 2,600 sleep centers in the country and SOD's channel partners behind us, we intend to take that test nationwide, and our FDA-cleared appliances treat the obstructive sleep apnea that may be contributing to the condition the test is designed to identify.”
LITTLETON, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos” or the “Company”) today announced that it has closed its acquisition of an 11% fully diluted equity interest in SOD Sciences, Inc. (“SOD Sciences” or “SOD”) and a 50% undivided co-ownership interest in SOD's pseudohypoxia early‑warning test, the "Primed Cell for Chronic Disease" test. In exchange, Vivos issued to SOD 12,000 shares of newly created Series C Convertible Preferred Stock with an aggregate stated value of $12 million. No cash consideration was paid by either party. Through the joint marketing arrangement to be negotiated with SOD following closing and SOD’s marketing relationship with Florida based CLIA-certified lab American Health Associates (“AHA”), Vivos also expects to obtain the opportunity to test and treat AHA’s more than 325,000 existing patients at approximately 3,000 assisted living facilities and nursing homes, many of whom are believed to be at elevated risk for OSA and for chronic diseases such as diabetes, cancer, and cardiovascular disease, subject to the negotiation and execution of definitive agreements and to final approval of the bankruptcy court in AHA’s pending bankruptcy proceeding.
Get started
Create a free account to read the full story.